These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31591336)

  • 1. Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults.
    Petráš M; Oleár V; Molitorisová M; Dáňová J; Čelko AM; Nováková E; Štefkovičová M; Krištúfková Z; Malinová J; Lesná IK
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31591336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
    Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
    Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of humoral immunity to tetanus and diphtheria in hematopoietic stem cell transplant recipients after post-transplant immunization.
    Škovránková J; Petráš M
    Pediatr Blood Cancer; 2012 Nov; 59(5):908-13. PubMed ID: 22514148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
    Blatter M; Friedland LR; Weston WM; Li P; Howe B
    Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R; Galtier F; Richard P; Baudin M
    Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
    Trollfors B; Knutsson N; Taranger J; Mark A; Bergfors E; Sundh V; Lagergård T
    Eur J Pediatr; 2006 Jan; 165(1):14-8. PubMed ID: 16249929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diphtheria booster immunization for adults].
    Hasselhorn HM; Nübling M; Tiller FW; Hofmann F
    Dtsch Med Wochenschr; 1997 Mar; 122(10):281-6. PubMed ID: 9102270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
    Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline immunity to diphtheria and immunologic response after booster vaccination with reduced diphtheria and tetanus toxoid vaccine in Thai health care workers.
    Wiboonchutikul S; Manosuthi W; Sangsajja C; Thientong V; Likanonsakul S; Srisopha S; Termvises P; Rujitip J; Loiusirirotchanakul S; Puthavathana P
    Am J Infect Control; 2014 Jul; 42(7):e81-3. PubMed ID: 24751139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. Munich Vaccine Study Group.
    Stojanov S; Liese JG; Bendjenana H; Harzer E; Barrand M; Jow S; Dupuy M; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jun; 19(6):516-21. PubMed ID: 10877165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
    Weston W; Messier M; Friedland LR; Wu X; Howe B
    Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.